• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Progyny Stock And 2 Fertility Shares Riding The IVF Genetics Shift

    Simply Wall St·10/25/2026 14:28:53
    語音播報

    Embryo gene editing is pulling IVF and fertility diagnostics out of the medical pages and into the mainstream, as venture capital backs controversial start ups and pushes reproductive genetics into the spotlight. Investor fear of missing a potential step change meets equally strong concern about ethics and regulation. This article unpacks that tension and profiles 3 stocks exposed to these headlines so you can consider how, or if, this theme fits your portfolio.

    The stocks profiled below are just a starting sample of the IVF and fertility diagnostics theme, and the full screen surfaced 10 more listed players with equally compelling narratives that do not fit into a single article. To see the wider field and identify which fertility care and reproductive testing businesses best match your criteria, head straight into the Public IVF and Fertility Diagnostics Providers screener to filter and analyze potential higher conviction ideas.

    BGI Genomics (SZSE:300676)

    Overview: BGI Genomics provides genomics research services and precision medicine testing, including reproductive health diagnostics that link directly to IVF and fertility workflows.

    Market Cap: CN¥15.6b

    BGI Genomics gives you exposure to reproductive and embryo screening demand through its broader genomics testing platform. Recent results show positive net income and steady revenue from genomic services that include fertility workflows. For investors focused on IVF and fertility diagnostics, the potential opportunity depends on how an unseen pressure on testing margins and pricing ultimately resolves.

    That pricing pressure is exactly why a closer look at the BGI Genomics financial health report can highlight whether BGI Genomics has the balance sheet strength to absorb it.

    SZSE:300676 Revenue & Expenses Breakdown as at Oct 2026
    SZSE:300676 Revenue & Expenses Breakdown as at Oct 2026

    Progyny (PGNY)

    Overview: Progyny runs an employer-sponsored fertility and family-building benefits platform that connects workers directly to IVF clinics, treatment coverage, and related reproductive care.

    Operations: Progyny generates US$1.3b in revenue from fertility, family building and women's health benefits solutions, all earned within the United States.

    Market Cap: US$2.2b

    For the Public IVF and Fertility Diagnostics Providers theme, Progyny matters because its benefits design, clinic network, and pharmacy support are all tied directly to IVF volumes and the growing use of embryo selection and genetic screening within employer plans.

    "Sustained high employer focus on fertility and women's health benefits, supported by management commentary about family building remaining a priority as overall medical costs rise at double digit rates, can continue to support Progyny's covered lives growth and future revenue."

    What happens to Progyny’s margins and growth if one unresolved cost pressure inside those employer benefits packages shifts more aggressively than expected?

    If that cost mix is what you are focused on, the full narrative for Progyny shows where Progyny’s model could either absorb the pressure or see earnings momentum stall.

    NasdaqGS:PGNY Revenue & Expenses Breakdown as at Oct 2026
    NasdaqGS:PGNY Revenue & Expenses Breakdown as at Oct 2026

    FamiCord (XTRA:V3V)

    Overview: FamiCord collects, processes, and stores human cells, tissues, blood, sperm, and oocytes, supporting fertility treatments and future regenerative therapies.

    Operations: FamiCord generates revenue of about €24 million in Poland, €13 million in Germany, €12 million in Switzerland, and €38 million across other countries.

    Market Cap: €47 million

    FamiCord sits closer to the infrastructure side of fertility care, linking IVF and perinatal medicine to long term storage of biological materials that could underpin future reproductive and cell based therapies.

    "Systematic roll out of placenta banking, which is more intuitively understood and accepted by doctors and parents, should lift conversion rates per birth and increase average revenue per client as uptake broadens across countries."

    The real swing factor for FamiCord is what happens if one quiet shift in how families value long term biobanking meaningfully changes demand.

    If that shift is what you are watching, the full narrative for FamiCord explains how changing family priorities could either accelerate FamiCord’s volumes or leave growth quietly stalled.

    XTRA:V3V Revenue & Expenses Breakdown as at Oct 2026
    XTRA:V3V Revenue & Expenses Breakdown as at Oct 2026

    Seeking Alternatives Before The Crowd?

    Fresh themes move first. By the time momentum headlines hit, early opportunities can be gone or prices already flying. Scan curated ideas while it matters and get in early.